Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-10-20
2009-11-17
Saoud, Christine J (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S069900, C435S483000, C424S093510, C424S009100
Reexamination Certificate
active
07618793
ABSTRACT:
Methods of screening candidate agents to identify potential therapeutic agents for the treatment of a neurodegenerative disease, such as Huntington's Disease and Parkinson's Disease and methods for identifying a mutation in, or changes in expression of, a gene associated with neurodegenerative disease, such as Huntington's Disease and Parkinson's Disease, are provided.
REFERENCES:
patent: 2003/0073610 (2003-04-01), Lindquist et al.
Li et al. Trends in Genetics 2004. 20:146-154.
/www.yeastgenome.org/sgdpub/Saccharomyces—cerevisiae.pdf.
Ambrose, C. et al., “Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat,”Somat. Cell. Mol. Genet.,20(1):27-38 (Jan. 1994).
Cowles, C. et al., “Mutations in theVPS45gene, aSEC1homologue, result in vacuolar protein sorting defects and accumulation of membrane vesicles,”J. Cell Sci.,107:3449-3459 (1994).
Dailey, D. et al., “Novel yeast protein kinase (YPK1gene product) is a 40-kilodalton phosphotyrosyl protein associated with protein-tyrosine kinase activity,”Mol. Cell. Biol.,10(12):6244-6256 (Dec. 1990).
Gusella, J. and Macdonald M., “Molecular genetics: Unmasking polyglutamine triggers in neurodegenerative disease,”Nat. Rev. Neurosci.,1(2):109-115 (Nov. 2000).
Hardy J. and Selkoe D., “The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics,”Science,297(5580):353-356 (Jul. 19, 2002).
Macdonald, M. et al., “A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes,” The Huntington's Disease Collaborative Research Group,Cell,72(6):971-983 (Mar. 26, 1993).
Meriin, A. et al., “Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1,”J. Cell. Biol.,157(6):997-1004 (Jun. 10, 2002).
Muchowski, P. et al., “Hsp70 and Hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils,”PNAS,97(14):7841-7846 (Jul. 5, 2000).
Rochet, JC and Lansbury, P., “Amyloid fibrillogenesis: themes and variations,”Curr. Opin. Struct. Biol.,10(1):60-68 (Feb. 2000).
Ross, C. and Poirier, M., “Protein aggregation and neurodegenerative disease,”Nat. Med.,10 Suppl:S10-S17 (Jul. 2004).
Scherzinger, E. et al., “Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo,”Cell,90(3):549-558 (Aug. 8, 1997).
Zoghbi, H. et al., “Glutamine repeats and neurodegeneration,”Annu. Rev. Neurosci.,23:217-247 (2000).
Muchowski, P. et al., U.S. Appl. No. 11/003,216, filed Dec. 3, 2004, entitled “Methods of Identifying Lead Compounds that Modulate Toxicity of Neurotoxic Polypeptides”.
Burger H., et al., “A genome-wide screening inSaccharomyces cerevisiaefor genes that confer resistance to the anticancer agent cisplatin,”Biochem. Biophys. Res. Commun.,269:767-774 (2000).
Chiarugi A., et al., “Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis,”Neuroscience,102(3):687-695 (2001), Abstract.
Cozzi A., et al., “Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia,”J. Cereb. Blood Flow Metab.,19(7):771-777 (1999), Abstract.
Meriin A., et al., “Aggregation of expanded polyglutamine domain in yeast leads to defects in endocytosis,”Mol. Cell. Biol.,23(21):7554-7565 (Nov. 2003).
Meriin A., et al., “Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1,”J. Cell Biol.,157(6):997-1004 (Jun. 10, 2002).
Moroni F. et al. “Studies on the neuroprotective action of kynurenine mono-oxygenase inhibitors in post-ischemic brain damage,”Adv. Exp. Med. Biol.,527:127-136 (2003).
Moroni, et al., “Neuroprotective effects of kynurenine-3-hydroxylase inhibitors in models of brain ischemia,”Adv. Exp. Med. Biol.,467:199-206 (1999), Abstract.
Munder T. and Hinnen A., “Yeast cells as tools for target-oriented screening,”Appl. Microbol. Biotechnol.,52:311-320 (1999).
Obrenovitch TP and Urenjak J., “In vivo assessment of kynurenate neuroprotective potency and quinolinate excitotoxicity,”Amino Acids,19(1):299-309 (2000), Abstract.
Perego P., et al., “Yeast mutants as a model system for identification of determinants of chemosensitivity,”Pharmacol. Rev.,52:477-491 (2000).
Richter A. and Hamann M., “The kynurenine 3-hydroxylase inhibitor Ro 61-8048 improves dystonia in a genetic model of paroxysmal dyskinesia,”Eur. J. Pharmacol.,478(1):47-52 (Sep. 2003), Abstract.
Rover S., et al., “Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase,”J. Med. Chem.,40(26):4378-4385 (Dec. 1997), Abstract.
Schwarcz R., “The kynurenine pathway of tryptophan degradation as a drug target,”Curr. Opin. Pharmacol.,4(1):12-7 (Feb. 2004), Abstract.
Urenjak J. and Obrenovitch TP., “Kynurenine 3-hydroxylase inhibition in rats: effects on extracellular kynurenic acid concentration and N-methyl-D-aspartate-induced depolarisation in the striatum,”J. Neurochem.,75(6):2427-2433 (Dec. 2000), Abstract.
Zysk J. and Baumbach W., “Homogeneous pharmacologic and cell-based screens provide diverse strategies in drug discovery: somatostatin antagonists as a case study,”Chomb. Chem. High Throughput Screen.,1:171-183 (1998).
Giorgini Flaviano
Muchowski Paul J.
Saoud Christine J
The Regents of the University of Washington
Townsend and Townsend / and Crew LLP
Wang Chang-Yu
LandOfFree
Identifying agents for decreasing cellular toxicity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Identifying agents for decreasing cellular toxicity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identifying agents for decreasing cellular toxicity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4065121